Status:
UNKNOWN
Safety and Performance of Vectorio® in Conventional Trans-Arterial Chemo-Embolization (cTACE): A Post-Market Clinical Follow-up
Lead Sponsor:
Guerbet
Conditions:
Oncology
Eligibility:
All Genders
18+ years
Brief Summary
This study is conducted within the frame of the Post-Market Surveillance (PMS) activities, as described in the Post Market Clinical Follow-up (PMCF) plan of Vectorio®. This study aims at collecting cl...
Eligibility Criteria
Inclusion
- Female or male adult patient older than 18 years
- Patient with confirmed diagnosis of HCC and eligible for cTACE procedure
- Patient affiliated to national health insurance according to local regulatory requirements
- Patient having read the information and having provided his/her consent to participate in writing by dating and signing the informed consent form
Exclusion
- Patient with contraindications to cTACE procedure
- Patient with known contra-indication(s) to the use or with known sensitivity to Lipiodol or chemotherapeutic agent
- Pregnant or breast-feeding female patient.
- Patient unlikely to comply with the CIP, e.g. uncooperative attitude and unlikelihood of completing the study
Key Trial Info
Start Date :
August 30 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 31 2023
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05316077
Start Date
August 30 2022
End Date
March 31 2023
Last Update
September 15 2022
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Univ.-Klinik für Radiologie
Graz, Austria
2
CHU-Hôpital François Mitterrand
Dijon, France
3
CHUV
Lausanne, Switzerland